First cancer drug to begin its clinical development in Taiwan

The NICR published the research result of “Nanoliposomal irinotecan with 5-fluorouracil and leucovorin in metastatic pancreatic cancer after prior gemcitabine-based therapy (NAPOLI-1): a global, randomized, open-label phase 3 trial. ” (Lancet 2016 Feb;387(10018):545-57). The article was reported in No. 631 of NHRI Communications (Chinese Version). 

First cancer drug to begin its clinical development in Taiwan

First cancer drug to begin its clinical development in Taiwan

Comments are closed.